Early switch from run-in with targeted to immunotherapy in advanced BRAF-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
E. Livingstone(Essen University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Jochen Utikal(German Cancer Research Center), Martin Hartmann(Heidelberg University), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Anja Gesierich(University of Michigan), Alexander Roesch(Essen University Hospital), P. Terheyden(University Hospital Schleswig-Holstein), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Željko Mijušković(Military Medical Academy), Friedegund Meier(National Center for Tumor Diseases), Sabine Eckhardt(NILU), H.J. Gogas(National and Kapodistrian University of Athens), Thomas Eigentler(University Children's Hospital Tübingen), Selma Ugurel(Klinikum Bielefeld), Dimitrios C. Ziogas(National and Kapodistrian University of Athens), C. Gaudy-Marqueste, Marlene Garzarolli, Lisa Zimmer(The University of Sydney), Mirjana Ziemer(University Medical Center), Felix Kiecker(Humboldt-Universität zu Berlin), Sebastian Miethe(Statistisches Bundesamt), Lidija Kandolf(Military Medical Academy), Claus Garbe(University of Tübingen)
Cited by 4
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k